Comorbid cerebral amyloid angiopathy in dementia and prodromal stages-Prevalence and effects on cognition.
Alzheimer's disease
cerebral amyoid agiopathy
cognition
mild cognitive impairment
mixed dementia
Journal
International journal of geriatric psychiatry
ISSN: 1099-1166
Titre abrégé: Int J Geriatr Psychiatry
Pays: England
ID NLM: 8710629
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
27
03
2023
accepted:
25
09
2023
medline:
23
10
2023
pubmed:
17
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
To determine the contribution of cerebral amyloid angiopathy to cognitive impairment in MCI and dementia. Patients with subjective memory impairment (SMI), amnestic and non-amnestic mild cognitive impairment ((n)aMCI), Alzheimer's disease (AD), mixed and vascular dementia (MD/VD) from our memory clinic were included in this retrospective analysis. Patients underwent neuropsychological testing and cranial magnetic resonance imaging (MRI). Magnetic resonance imaging data sets were analyzed regarding the presence of CAA-related MRI biomarkers to determine CAA prevalence. ANOVAs were used to investigate the contribution of CAA to cognitive impairment within diagnostic groups and to determine whether differences in cognitive test performance between the diagnostic groups are mediated by total CAA burden. 475 patients (222 male, 253 female) with SMI (n = 47), naMCI (n = 41), aMCI (n = 189), early AD (n = 9), AD (n = 114), MD (n = 71) and VD (n = 4) were included. Mean age was 73.2 (9.9) years. CAA prevalence was 14.9% in SMI, 14.6% in naMCI, 24.3% in aMCI, 22.2% in early onset AD, 18.4% in late onset AD, 46.5% in MD and 25% in VD. Patients with possible and probable CAA were older than patients without CAA. In particular, diagnosis of aMCI, early onset AD, MD and VD showed high CAA prevalence. In AD but not in aMCI, CAA diagnosis significantly influenced test performance in the CERAD word list recall (F (1,78) = 4505; p = 0.037; partial eta-square = 0.055). Differences in cognitive test performance between the diagnostic groups of naMCI, aMCI, AD and MD were mediated by total CAA burden within AAT simply nouns subtest (F (2,39) = 4059; p = 0.025; partial eta-square = 0.172) and in CERAD verbal fluency test (F (3,129) = 3533; p = 0.017; partial eta-square = 0.076). This retrospective analysis demonstrates high prevalence rates of CAA in cognitive diagnoses. Our data suggest that comorbid CAA independently impacts cognitive test performance in the course of AD with presumably stage-dependent effects. Especially in patients with AD comorbid CAA additionally impairs memory function. Total CAA small vessel disease burden further modulates psychometric differences in cognitive test performance between diagnostic groups regarding word finding and word fluency capabilities.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e6015Informations de copyright
© 2023 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
Références
Thal DR, Griffin WS, de Vos RA, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. Acta Neuropathol. 2008;115(6):599-609. https://doi.org/10.1007/s00401-008-0366-2
Greenberg SM, Vonsattel JP. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke. 1997;28(7):1418-1422. https://doi.org/10.1161/01.str.28.7.1418
Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol. 2011;70(6):871-880. https://doi.org/10.1002/ana.22516
Keage HA, Carare RO, Friedland RP, et al. Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol. 2009;9(1):3. https://doi.org/10.1186/1471-2377-9-3
Jellinger KA. Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm. 2002;109(5-6):813-836. https://doi.org/10.1007/s007020200068
Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. Neurology. 2015;85(22):1930-1936. https://doi.org/10.1212/wnl.0000000000002175
Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol. 2011;69(2):320-327. https://doi.org/10.1002/ana.22112
Xiong L, Boulouis G, Charidimou A, et al. Dementia incidence and predictors in cerebral amyloid angiopathy patients without intracerebral hemorrhage. J Cerebr Blood Flow Metabol. 2018;38(2):241-249. https://doi.org/10.1177/0271678x17700435
Durrani R, Wang M, Cox E, et al. Mediators of cognitive impairment in cerebral amyloid angiopathy. Int J Stroke. 2023;18(1):78-84. https://doi.org/10.1177/17474930221099352
Costa AS, Pinho J, Kucikiene D, Reich A, Schulz JB, Reetz K. Cerebral amyloid angiopathy in amyloid-positive patients from a memory clinic cohort. J Alzheimers Dis. 2021;79(4):1661-1672. https://doi.org/10.3233/jad-201218
Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease-one peptide, two pathways. Nat Rev Neurol. 2020;16(1):30-42. https://doi.org/10.1038/s41582-019-0281-2
Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet. 1999;354(9182):919-920. https://doi.org/10.1016/s0140-6736(99)02355-7
Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813-817. https://doi.org/10.1001/jama.277.10.813
Subotic A, McCreary CR, Saad F, et al. Cortical thickness and its association with clinical cognitive and neuroimaging markers in cerebral amyloid angiopathy. J Alzheimers Dis. 2021;81(4):1663-1671. https://doi.org/10.3233/jad-210138
Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ. Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology. 2002;58(11):1629-1634. https://doi.org/10.1212/wnl.58.11.1629
Hecht M, Kramer LM, von Arnim CAF, Otto M, Thal DR. Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathol. 2018;135(5):681-694. https://doi.org/10.1007/s00401-018-1834-y
Greenberg SM, Gurol ME, Rosand J, Smith EE. Amyloid angiopathy-related vascular cognitive impairment. Stroke. 2004;35(Suppl l):2616-2619. https://doi.org/10.1161/01.str.0000143224.36527.44
Drenth N, van der Grond J, Rombouts S, et al. Cerebral amyloid angiopathy is associated with decreased functional brain connectivity. Neuroimage Clin. 2021;29:102546. https://doi.org/10.1016/j.nicl.2020.102546
Xiong L, Davidsdottir S, Reijmer YD, et al. Cognitive profile and its association with neuroimaging markers of non-demented cerebral amyloid angiopathy patients in a stroke unit. J Alzheimers Dis. 2016;52(1):171-178. https://doi.org/10.3233/jad-150890
Abdulrab K, Heun R. Subjective Memory Impairment. A review of its definitions indicates the need for a comprehensive set of standardised and validated criteria. Eur Psychiatr. 2008;23(5):321-330. https://doi.org/10.1016/j.eurpsy.2008.02.004
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279. https://doi.org/10.1016/j.jalz.2011.03.008
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183-194. https://doi.org/10.1111/j.1365-2796.2004.01388.x
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology. 1984;34(7):939-944. https://doi.org/10.1212/wnl.34.7.939
Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28(3):206-218. https://doi.org/10.1097/wad.0000000000000034
Charidimou A, Martinez-Ramirez S, Reijmer YD, et al. Total magnetic resonance imaging burden of small vessel disease in cerebral amyloid angiopathy: an imaging-pathologic study of concept validation. JAMA Neurol. 2016;73(8):994-1001. https://doi.org/10.1001/jamaneurol.2016.0832
Haller S, Vernooij MW, Kuijer JPA, Larsson EM, Jager HR, Barkhof F. Cerebral microbleeds: imaging and clinical significance. Radiology. 2018;287(1):11-28. https://doi.org/10.1148/radiol.2018170803
Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-356. https://doi.org/10.2214/ajr.149.2.351
Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018;49(2):491-497. https://doi.org/10.1161/strokeaha.117.016990
Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology. 2001;56(4):537-539. https://doi.org/10.1212/wnl.56.4.537
Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology. 2010;74(17):1346-1350. https://doi.org/10.1212/wnl.0b013e3181dad605
Neubauer AC, Grabner RH, Freudenthaler HH, Beckmann JF, Guthke J. Intelligence and individual differences in becoming neurally efficient. Acta Psychol. 2004;116(1):55-74. https://doi.org/10.1016/j.actpsy.2003.11.005
Kessler J, Fast K, Mielke R. [Premorbid intelligence diagnosis with the MWT-B(multiple Choice word test-B) in patients with Alzheimer disease]. Nervenarzt. 1995;66:696-702.
Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, Bennett DA. Person-specific contribution of neuropathologies to cognitive loss in old age. Ann Neurol. 2018;83(1):74-83. https://doi.org/10.1002/ana.25123
Jakel L, De Kort AM, Klijn CJM, Schreuder F, Verbeek MM. Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis. Alzheimers Dement. 2022;18(1):10-28. https://doi.org/10.1002/alz.12366
Ryu SY, Lim EY, Na S, et al. Hippocampal and entorhinal structures in subjective memory impairment: a combined MRI volumetric and DTI study. Int Psychogeriatr. 2017;29(5):785-792. https://doi.org/10.1017/s1041610216002349
Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol. 2017;13(1):369-396. https://doi.org/10.1146/annurev-clinpsy-032816-045136
Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361(3):255-263. https://doi.org/10.1056/nejmoa0809437
Rannikmae K, Samarasekera N, Martinez-Gonzalez NA, Al-Shahi Salman R, Sudlow CL. Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84(8):901-908. https://doi.org/10.1136/jnnp-2012-303898
Charidimou A, Boulouis G, Gurol ME, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain. 2017;140(7):1829-1850. https://doi.org/10.1093/brain/awx047
Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: mild cognitive impairment: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology. 2018;90(3):126-135. https://doi.org/10.1212/wnl.0000000000004826
Malek-Ahmadi M, Perez SE, Chen K, Mufson EJ. Braak stage, cerebral amyloid angiopathy, and cognitive decline in early Alzheimer’s disease. J Alzheimers Dis. 2020;74(1):189-197. https://doi.org/10.3233/jad-191151
Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19(3):271-278. https://doi.org/10.1016/s1474-4422(19)30368-0